12345...102030...


At least we’ve on from eugenics…maybe – The Irish Catholic

Arecurring line from the Twilight Zone movie came back to me last week: You want to see something really scary?

Eugenics: Sciences Greatest Scandal (BBC4) over the last two Thursdays made for very scary viewing. Were familiar with eugenics, pure race theory and the like from Nazi ideology, but the programmes showed that the seeds of it began in Britain.

Journalist Angela Saini and Adam Pearson were in no doubt about the ugliness and evil consequences of this patronising an arrogant ideology, where the individual was sacrificed, ostensibly for the good of society and the gene pool.

We heard the ideology described as bizarre, creepy, this terrible idea, malicious and terrifying. The language of the eugenicists was repulsive, with quotes like imbecile girl, mentally defective family, parasitic race, superior stocks and racial hygiene.

Prominent figures were in the dock apparently Churchill was a fan of eugenics, at least before World War II, and several prominent scientists developed and promoted it, even though it took the Nazis to follow it to the conclusion that the weak, infirm and disabled should be experimented on and murdered.

Likewise with Marie Stopes (she of the clinics) she promoted birth control for the poor so that they wouldnt reproduce so much. I was glad to see that the Catholic Church and some MPs successfully campaigned to halt forced sterilisation in Britain in the early 20th Century.

Its easy to see the moral failures of the past and be smug about it, when maybe we should just be glad weve moved on and learned lessons, but the programme suggested that maybe we havent moved on.

At the start of last weeks episode we saw protests from the Dont Screen Us Out campaign against the aborting of babies because they have Downs syndrome. In fact abortion had been used in Britain in the past when efforts to stop the mentally defective from procreating didnt work. And it definitely rang a bell when I heard of two doctors casually certifying a woman, Mabel Cooper, as unfit and incarcerating her into an institution unbelievably in 1957.

Eventually she got out, received an honorary degree and ran a disability rights campaign.

That latest episode dealt with more contemporary manifestations of eugenic ideology, for example the worrying news that it continued after the second world war and fed into forced sterilisations, apartheid and far-right ideology (do media people ever worry about the far left?).

The eugenicist attitudes of birth control advocate Margaret Sanger (she of Planned Parenthood) was also outlined. Fears were also expressed about modern scientific developments, especially non-invasive screening of babies in the womb leading to the destruction of most unborn babies diagnosed with Downs syndrome (90% in the UK we were told).

Finally, compliments to RT and EWTN for live coverage of the canonisation ceremony for Cardinal Newman. It was quite an event, with significant relevance for Ireland, and also it wasnt until the live coverage that I got a handle on the four holy women that were canonised as well.

The Leap of Faith (RT Radio 1) was early into the breach two Fridays ago with an informative interview with Newman biographer Fr Dermot Mansfield. He described the saint as a man of integrity, truth, humanity and prayer.

Last weekends Sunday programme on BBC Radio 4 featured a thorough and very positive exploration of Newmans life and influence. They reported one priest claiming that Newman would have been a remainer in relation to Brexit a rather large and divisive assumption!

This was followed by a dignified service from the Birmingham Oratory, where Newman ministered. This newspapers Managing Editor editor Michael Kelly contributed to Sunday Sequence (BBC Radio Ulster), pointing out how the gathering in Rome illustrated the universality of the Church, stressing how Newman can be a unifying figure in a Church with divisions and drawing attention to the hastily arranged visitof an Irish Government representative to the event.

On Sunday Morning Live (BBC1) Bishop John Arnold of Salford emphasised how Newman was both intellectual and pastoral in his approach. Later on Songs of Praise (BBC One, Sunday) Rev. Kate Bottley visited Birmingham Oratory where we got a look at Newmans study, left as it was when he died. Fr Anton Guziel pointed out how Neman ministered to the rich and the very poor.

I hope all the coverage inspires more people to look into the saints writings.

****

Mass for Mission Sunday with music from the choir of the National Centre for Liturgy, St Patricks College, Maynooth. Co-celebrants are Fr Frank Conlisk and Fr Martin Smith.

Joe Duffy narrates the story of a Dublin priest and amateur filmmaker, Fr Jack Delaney, who captured all walks of Irish life in the days before television.

This special programme takes a close look at the role that plants and gardening play in mental and physical wellbeing, exploring the idea that gardening is good for you.

Related

Continued here:

At least we've on from eugenics...maybe - The Irish Catholic

New Governor Addresses Piney Situation – By THOMAS P. FARNER – The SandPaper

Surf City Beginning in 1912, the people of the New Jersey Pine Barrens were under attack and faced extermination. It didnt come from an enemy army or disease, but from the modern science of eugenics and the progressive political movement of the day. Two government-funded reports had labeled the residents in the press as incestuous inbreeders who lived a life of crime. Soon, shouts of what will we do with those people resounded from the states urban centers. It wasnt long until the politicians answered the call.

The April 23 edition of the Camden Courier reported, The startling conditions that have been reported as existing in the pines of Burlington county, by Miss Elizabeth Kite, will be investigated by the grand jury summoned at the opening of the term of court of Burlington county yesterday. Action along this line has been caused by the publication of Miss Kites report. Attracted by Miss Kites touch upon the alleged unlawful conditions and responding to suggestions made by the public press, Prosecutor Atkinson had Miss Kite summoned to appear before the grand jury.

On May 13, the Asbury Park Press told readers there had been some action.

The grand jury also disposed of its investigation into alleged immoral conditions in the pines of Burlington county, as presented in recent reports by Miss Elizabeth S. Kite. There was action in one case, Gardner Hendrickson of Southampton township, being indicted for bigamy. He thought, he declared, because his wife had married his brother, he had a right to marry another woman.

The problem was also handed over to the state saying, The grand jury in its presentment stated that it was the duty of the state to provide that the propagation of deficient classes be stopped by the enforcement of adequate laws made for the purpose.

By the spring of 1913, Gov. Woodrow Wilson, who signed a bill authorizing forced sterilizations, had left the state to become president, leaving behind his hand-picked choice, James Fiedler, to serve as temporary governor.

On June 26, the Paterson Call announced, Acting Governor Fielder, moved by the recent report of Miss Kite on immorality in the section of South Jersey known as the pine belt, will make a personal tour of inspection tomorrow to study the habits of the people in that section. The executive intends to spend the entire day in the country embraced in the exhaustive report of Miss Kite. If there is any immorality going on Mr. Fielder wants to see it.

Today what took place would be called a media circus, as a governor went in search of immorality. The Asbury Park Press of June 28 explained, Following a strenuous days tour of the notorious belt the executive diagnosed the trouble with the inhabitants of the pine lands. Discussing the subject with a staff reporter from The Press he set forth his views in no uncertain words. He laid the blame to a great extent at the door of those who live among the people whose morality is practically null and who have raised no hand to aid them. (H)e suggested that he would use his influence to bring the grand juries of the counties affected to indict those whose vices are responsible for the mental, moral and physical degeneration of the inhabitants of the belt.

The governor had other dignitaries traveling with him.

The Rev. A.W. Bostwick a member of the party who made the tour suggested during the day that the state establish segregation colonies where the mentally defective could be sent and where the immoral could be detained. Even more radical surgical steps toward the obliteration of the deplorable conditions were spoken of but neither appealed to the executive as practical. In the former case the segregation, it was argued might work toward the introduction of more revolting actions and the second would require trial.

Being a good politician and thinking about re-election, Fielder proposed a gentler remedy.

He advocated the introduction of properly censored motion pictures, illustrated lectures, and any form of amusement that would serve to interest the people in a cleaner form of living. He said that from his observations he did not think that it was due so much to the fact that they were imbued with a desire toward immorality as it was that they were uneducated, illiterate. They must first be taught what they must not do and then it will be time to show what they must do. On his trip today he found much that needed immediate remedy.

The Press concluded, The need of social workers was strongly apparent to the governor when he entered a little two room house where the front room served, he said, for living room, bed room, kitchen, dining room and hen house. He said that while he was in the front room the chickens were walking over the bed, and the house was in a filthy condition. In the heart of one of the principle towns in the belt he found a man and woman dwelling together with children, tho, they had never been married. Everyone in town knew it, he said but paid no heed to the effects that might come.

While the Asbury Park newspaper was generally sympathetic, the New York Sun took a hard line.

NEW JERSEY should do something quickly about the Pineys, that degenerate race which dwells in the sand and pine barrens in the heart of the State, decided acting Governor James E. Fielder on Friday night after an all-day trip through the wilder parts of Burlington county. Not much longer should these degenerate descendants of a fine stock be allowed to multiply and inbreed to swell the States list of public charges, he declared. Segregation will be tried and perhaps sterilization to stop the birth of idiots and criminals and defectives. Social centres are to be established in the little red school-houses. The decent folk of the district are to be pilloried if they do not see that the law is enforced against their worthless neighbors.

To the Sun, Fiedler didnt seem as kind.

I have been shocked at the conditions I found. Evidently these people are a serious menace to the state of New Jersey because they produce so many persons that inevitably become public charges. They have inbred and led lawless and scandalous lives till they have become a race of imbeciles, criminals and defectives.

The state must segregate them, that is certain. I think it may be necessary to sterilize some of them. They tell me there are as many as 1,500 right here in Burlington county and several thousand in the pine belt of the state.

For the children we must have social centers in the schools, and these would do something for the grown persons. There must be sharp heed that the children attend school, and it will be possible to educate parents in many cases.

He concluded his interview with The low mentality of these people is the great handicap, and it is plainly responsible for the low moral standards among them. Lack of education is another factor, and the universal poverty and the fact that the children all have to go to work at a tender age contribute to keep these people down. But from what I have seen today I believe that the Pineys largely know their plight. They are now generally sending their children to school. They are no longer indifferent to whether the child can read or write. There is hope for a race that knows where it stands. But I will act on the situation at once.

Segregation camps and sterilization or movie theaters and recreation centers which way would the state of New Jersey go when it came to dealing with those people in the pines?

Next Week: the colony.

tpfcjf@comcast.net

See the article here:

New Governor Addresses Piney Situation - By THOMAS P. FARNER - The SandPaper

5-year-old find gun on school property in Madison – Houston Chronicle

MADISON, Wis. (AP) Police say a 5-year-old student found a handgun in the grass at a Madison elementary school.

Police spokesman Joel DeSpain says the child found the unloaded gun shortly before 6 p.m. Tuesday at Leopold Elementary School. DeSpain says a school employee who happened to be in the area took the gun from the child.

The State Journal says an investigation is underway into who left or tossed the gun on school property.

___

Information from: Wisconsin State Journal, http://www.madison.com/wsj

See original here:

5-year-old find gun on school property in Madison - Houston Chronicle

Universities must stop covering up racism in order to protect their own reputations – The Guardian

The extent of racism in UK universities has been yet again exposed by a new Equalities and Human Rights Commission (EHRC) report. But while statistics like the fact that more than a quarter of minority ethnic students have faced both physical and verbal racist attacks are shocking, theyre not new. Last year the Student Room found that one in two students had witnessed or faced racism on campus, while a National Union of Students (NUS) report said that incidents of racism made students of colour want to discontinue their education.

I have heard anecdotes such as these firsthand. When the EHRC enquiry was launched I was serving as black students officer at the NUS, where I was regularly contacted by students of colour to support them with the racism they were experiencing on and off campus. Some of these stories made it into the news, with stories of leaked Facebook and WhatsApp chats, pictures of socials, and videos in halls going viral.

These stories and statistics can no longer be waved away as an aberration or minor part of some peoples experiences. For students of colour, racism is a constant in their lives. It is woven into every part of their so-called student experience, from being freshers to finding employment. For black, Asian and minority ethnic (BAME) staff, the challenge of getting a job in a university is surpassed only by the difficulty in getting promoted in a profession in which only 0.6% of UK professors are black. Although some universities have begun to make progress on these issues, often by using the Race Equality Charter framework, too many are sitting idly by and failing students and staff.

The problem is that racism and other forms of oppression are not something institutions want to readily admit exist, let alone begin the difficult work of rectifying. The marketisation of higher education has led to universities shifting focus from teaching and learning to protecting their reputations for fear of dropping in the league tables and losing out on students. In such a system, how can we expect universities to address racism, when the threat of bankruptcy looms with every low student intake? Meanwhile universities that are successful enough to expand are incentivised to increase their surplus, rather than looking after their students by increasing student support services or grants to the students union.

The focus on protecting the reputation of the institution was a theme of the EHRC report. One student said their university was more bothered about covering the incident up to maintain a spotless reputation than it was about tackling racism. Universities have begun to fear that talking openly about racism will deter potential applicants, but an honest conversation about race in our universities is desperately needed. This has been called for by students, staff and academics for decades, but has gained momentum over the past few years with the Why is my curriculum white? and decolonising movements enabling people to articulate their visions of a fairer campus.

For far too long universities have been exempt from public criticism thanks to their perception as elevated spaces of knowledge; places where liberalism and tolerance rule and which have meritocracy at their very heart. But studies like the EHRC report or research by the NUS black students campaign have begun to tear down this myth.

Yet for many, this myth never existed. Their experience at university isnt discussing lofty ideas in dreaming spires. Its being stopped by security; being asked to represent your people in a seminar; watching your junior colleagues getting promoted above you; being fearful of being referred to the home office at every student demonstration you attend; hearing lecturers use the n word; not using your ethnic name when applying for graduate schemes and fearing the prevent duty.

The truth is that from a historical perspective, universities have never been meritocratic or liberal. Many were created with the sole purpose of enabling people of wealth and prestige to accumulate further wealth and prestige. Their legacy includes training the next generation of people to run the British empire, funding from slavery and intellectualising eugenics to justify the racism on which the empire was built.

The writing is once again on the wall, and universities have a choice to make. They can continue to resist calls to change by hiding behind their reputations. Or we can finally see the tearing down of the myth of the liberal, tolerant institution and the creation of a progressive, democratic alternative.

Read more:

Universities must stop covering up racism in order to protect their own reputations - The Guardian

Teacher who called parent N-word in parking lot resigns – Houston Chronicle

UPPER DARBY, Pa. (AP) A white Pennsylvania teacher who was captured on video calling a black parent a racist slur following a fender bender has resigned.

The Upper Darby school board voted unanimously Tuesday to accept Drexel Middle School teacher Renee Greeley's resignation, effective Oct. 17.

Greeley was placed on administrative leave after parent Rasheed Noel posted video Oct. 10 of the minor car accident in the school parking lot. Greeley could be heard saying Noel is "probably on welfare" and should go back to his "Section 8 house." She later called him the N-word.

Greeley had taught in the district since 2008.

Nearly half of the district's 12,500 students are black.

Continue reading here:

Teacher who called parent N-word in parking lot resigns - Houston Chronicle

Trump Makes Startling Statement: ‘We’ve Taken Control of the Oil in the Middle East US Has Control of That’ – The New Civil Rights Movement

This Dystopian Hell Hole Nightmarish Hellscape That Democrats Are Putting Out

Whoopi Goldberg repeatedly fact-checked Meghan McCains analysis on The View of Sen. Bernie Sanders remarks about population control in light of climate change.

The Democratic presidential candidate agreed that family planning was a key feature in addressing climate catastrophe, and McCain backed her friend S.E. Cupps assessment of the remarks as an endorsement of eugenics.

Population growth is on the decline, McCain said. The worlds population is projected to nearly stop growing by the end of the century and in all clarity, I think people know this, but S.E. Cupp is one of my closest friends, and I agree with that. We were actually texting each other when this moment happened in the climate change debate.

Any time youre talking about population control, she added, if youre a pro-life person, it starts sounding alarms. Because, again, like in China they enacted a one-child policy, and now men outnumber women by 70 million in China and India. Its disgusting.

Related: Gross Distortion: S.E. Cupp Roasted for Insane Attack Accusing Bernie Sanders of Promoting Eugenics

Co-host Sunny Hostin pointed out that wasnt eugenics, which Goldberg had already defined earlier in the discussion, but McCain pressed on.

I believe its a slippery slope towards that, McCain said, and I do think this dystopian hell hole nightmarish hellscape that Democrats are putting out that climate change is just going to end everything to the (point) that were going to have to have population control in this country seems very extreme.

McCain and Abby Huntsman agreed that Sanders seemed to be supporting population control through abortion, while Hostin and Joy Behar argued thats not was he was saying at all and Goldberg cut in with a fact check.

Lets be clear about what he is saying, Goldberg said. Lets not make something up when its not what he said, because when you bring in eugenics, thats a different conversation. That is the controlling of a population because you dont like the size of your nose or theyre too dark.

McCain interjected to say that eugenics disproportionately impacts minorities and people with disabilities, but Goldberg said that was beside the point.

Eugenics doesnt have anything to did with minorities or anybody else, Goldberg said, over McCains protest, and I will say this to you also. Think about all the women in Ireland who for years just wanted birth control, they just wanted birth control because they live in a Catholic country that said you cannot have it.

They were having an insane amount of children, Goldberg added. What these women fought for and pressed for and marched for and got was the right to make that decision for themselves. I think thats clearly and maybe I misinterpreted it, but when he says, I think especially in poor countries around the world, where women do not necessarily want to have large numbers of babies, and where they can have the opportunity through birth control to control the number of kids they have, thats something I support. Thats different than eugenics.

McCain said she heard Sanders through the prism of a conservative, and she was alarmed.

I was shocked by what was coming out of his mouth, McCain said, and clearly everyone else at the table thought it was normal and just in the vein of climate change.

Huntsman was also alarmed, and the panelists argued over Sanders meaning, but Goldberg stepped back in again to restore order.

Listen, you can be pissed at what he said all you want to, she said, but report it correctly.

Excerpt from:

Trump Makes Startling Statement: 'We've Taken Control of the Oil in the Middle East US Has Control of That' - The New Civil Rights Movement

The Climate Change Solution Scientists Have Been Overlooking – Mother Jones

Overpopulation is a major contributor to climate change, but according to new research, a solution is lying in plain sight: increased access toeffective contraceptives.

Global climate change represents a grave threat to the future of human welfare and our natural environment, write doctors John Bongaarts and Rgine Sitruk-Ware of the Population Council in New York in an article published Tuesday in BMJ Sexual & Reproductive Health. The contentious ongoing policy debate about potential interventions focuses on switching to renewable energy sources and increasing energy use efficiency. But given the urgency of the problem and the lack of political will, other approaches to limit greenhouse gas emissions should be given higher priority. Improving access to effective contraception is one such policy that has thus far been largely ignored by the international climate community.

The authors claim that improved access to contraception could slow population growth and thereby reduce long-term greenhouse gas emissions globally by 40 percent or more. Bongaarts and Sitruk-Ware write that many married womenmore than half in some countrieswho do not wish to become pregnant still fail to use contraception due to barriers to access, high costs, and social stigma. Consequently, there are about 99 million unintended pregnancies worldwide each year. By 2100, Earths population is expected to reach 10.9 billion people. (The current population is about 7.7 billion.)

As Paul Ehrlich, author ofThe Population Bomb, toldMother Jones in 2010, overpopulation, combined with overconsumption, is the elephant in the room in climate discussions. We dont talk about overpopulation because of real fears from the pastof racism, eugenics, colonialism, forced sterilization, forced family planning, plus the fears from some of contraception, abortion, and sex. We dont really talk about overconsumption because of ignorance about the economics of overpopulation and the true ecological limits of Earth.

Bongaarts and Sitruk-Ware recommend that governments worldwide increase access to contraceptives by investing in family planning programs. They also encouragethe research and development of new forms of contraception, and they suggest combatting social opposition to birth control through media campaigns.

Wider distribution of contraceptives already on the market through greater investment in voluntary but underfunded family planning programmes is sufficient to raise contraceptive use substantially, they write. This in turn would have a profound positive impact on human welfare, the climate and the environment.

The rest is here:

The Climate Change Solution Scientists Have Been Overlooking - Mother Jones

Eugenics: The Scientific Scandal That Helped Hitler Murder 300,000 Disabled People – Newsweek

Eugenics is a concept often associated with the horrors of Nazi Germany. But, as disability rights activist Adam Pearson explores in a new documentary series, the ideology had its roots in 19th century Britainand still affects people alive today.

Known as the "father of eugenics," British Victorian scientist and statistician Sir Francis Galton developed the since debunked theory that individuals deemed "superior" according to factors such as their race or class could be socially engineered. Those regarded as biologically inferior and "feeble-minded" should, meanwhile, be prevented from having children, he argued.

Cherry picking the theories of his cousin Charles Darwin, who pioneered the theory of evolution, Galton developed a ranking of humansfor instance placing Australian Aborigines one "grade" below Africans.

In the decades that followed, these ideas have inspired horrifying policies from the murder of thousands of disabled people in Nazi Germany, to the sterilization of tens of thousands of people in the U.S. in the early 20th century.

Newsweek asked Pearson, a presenter and anti-bullying campaigner, what he learned while filming BBC Four's Eugenics: Science's Greatest Scandal Pearson alongside science journalist Angela Saini.

Were theories related to eugenics dark from the start, or did they come from a place of genuine scientific curiosity and later misused?

Everything comes from a place of curiosity, and science is a weapon of great power for change. The extent to which change happens, and more significantly, how it is allowed to happen, all comes down to those people who are wielding it. In this instance, the power was in that hands of well-thought of men whoin what we now know to be misusewas left to go unchallenged.

What are some policies that were influenced by or based on the theories of eugenics?

One of the big ones, as pertains to disability, was The Mental Deficiency Act of 1913. Whilst the act wasn't used until 1919, due to us [Britain] being at war, what it meant was that individuals whom were deemed "imbeciles" on grounds of both intellect and morality, could be segregated from society and literally locked away in an asylum. The number involved and the loss of freedom, with the benefit of retrospection, is truly shocking and heart breaking.

What were the most shocking things that you learned while filming this program?

We went to one of the earliest of examples of these asylums in Leeds [U.K.], a place called Meanwood Park. Mark Davis [a photographer and archivist] who I met was fascinated by the whole place and has kept loads of archives from its history.

If you add up the amount of years served by its 35 longest-serving inmateswho had committed no crime other than being disabledit comes to just under 2,000 years. Truly heartbreaking.

Read more

Do any moments from filming the program stand out to you?

There was no one moment in particular, but there was an overwhelming sense of "this would have been me." Had I been born in those times I'd definitely been sent to one of these asylums, or even worse taken to a Nazi Aktion T4 camp and executed as one the 300,000 disabled people murdered under Hitler's regime.

As a disability rights activist, how did learning about eugenics and creating this documentary make you feel?

I've honestly been all over the spectrum of emotions. I've felt seething anger, great sorrow and even mild heartbreak. I interviewed a man called Harvey Waterman [a man in his eighties] who was kept in one of these asylums, a place called St. Lawrence's [in Caterham, Surrey, U.K.]

As a journalist and activist, I'm no stranger to pain, but this is the only interview where I have to take a break halfway through. I pretended to need to toilet and had to take time to pull myself together. Though, more importantly, I felt inspired and hopeful. Having met several other activists, alongside medical professions and scientists, I believe the weapons of science are now in safer hands.

How much did you know about the history of eugenics before you started filming? Do you think it is a topic there is enough awareness of?

I knew the term, as should everyone, though I was unaware of the extent of how well respected it was. Even Winston Churchill [British Prime Minister during the World War II] was a heavy endorser of eugenics and what it stood for.

Are people still suffering from the effects of the ideology? I believe you met a woman who was sterilized?

Yes, Elena [Gorolova]. She was sterilized due to medical complications during child birththat was the medical answer. However, there are a disproportionate number of Roma Gypsy women from her country of Czechia who this has happened to.

She set up a campaign group and after years of fighting for justice politicians, finally passed a bill in order to compensate them. It just proves that while the term eugenics has been laid to rest, eugenic thinking is still alive, well and thriving in society.

Amid a divisive political climate which saw white supremacists rally in Charlottesville in 2017, do you worry that the theories of eugenics will drawn upon once again?

I do, but by the same token I like to think that we have learned enough from the past to be able to halt such propaganda and eugenic thinking as and when it arises.

Moving forward, how can we avoid ideas reminiscent of eugenics becoming widespreadparticularly as scientists make breakthroughs in fields like genetics and so-called human enhancement?

We have a whole area of science called bioethics, whose sole job is to ensure that this whole "designer baby" debate doesn't happen, and that science and medicine are always used for the betterment of patients, not to make a master society.

What do you want viewers to take away from the documentary?

That eugenics has a history and that it affects all of us. It isn't just a disabled issue, or Jewish issue. It's a humanity issue. I want people to watch this and feel the weight of the issue like Angela and I did. If this documentary makes you feel highly uncomfortable then good, it should.

See original here:

Eugenics: The Scientific Scandal That Helped Hitler Murder 300,000 Disabled People - Newsweek

What’s on TV tonight: The Met investigates London’s drugs gangs, and celebrities head to the First Dates Hotel – iNews

CultureTVPlus: a third season of Young Sheldon begins, and Catherine the Great is pining for her lover

Thursday, 10th October 2019, 15:51 pm

PICK OF THE DAY

The Met: Policing London

Deadly stabbings and shootings almost seem to be a daily occurrence in Englands capital, with a dramatic rise in the murders of under-25s in 2018 the year during which this excellent blue-light series was filmed. The programme begins with the distressing phone call made by 22-year-old youth worker Kobi Nelson after he was fatally stabbed. DNA from the crime scene matches that of a known 20-year-old and indicated that Nelsons killing might be related to drugs gangs. Five weeks later, Kelvin Odunuyi is shot dead at a cinema in Wood Green, leaving DCI Luke Marks and his team to determine whether it was connected to the earlier murder.

Young Sheldon

Inside Prison: Britain Behind Bars

This eye-opening docuseries lifting the lid on life behind bars focuses on HMP Isle of Wight, a specialist prison housing many sex offenders and paedophiles. Intelligence has been gathered that a USB stick containing child pornography is doing the rounds, so the officers launch a search. But finding such a small item in a vast prison is no easy task. The staff are also seen trying to combat the increasingly creative ways to smuggle drugs into the jail, from letters sprayed with a spice solution to hollowed-out chess pieces.

Celebrity First Dates Hotel For SU2C

Eugenics: Sciences Greatest Scandal

Eugenics did not die with the Nazis, argue science journalist Angela Saini and disability campaigner Adam Pearson in the second part of their penetrating look at the idea that, for the betterment of the human race, some people shouldnt be allowed to reproduce. Programmes of selective breeding to weed out disability and the mass sterilisation of the poor in so-called third world countries have continued, while emerging science such as gene editing could be leading to a new era of eugenics.

Catherine The Great

Helen Mirrens Russian empress is pining for her lover, Major General Potemkin (the man after whom the mutinous battleship was named), but he is away fighting the Turks a suddenly topical plot development given a certain US politicians late-night tweets. War, war, war! All I want to do is talk about sex, complains Catherine, as Paul Kaye joins the cast as a murderous peasant with radical views.

Continue reading here:

What's on TV tonight: The Met investigates London's drugs gangs, and celebrities head to the First Dates Hotel - iNews

Selling Babies, Trading Wives – By THOMAS P. FARNER – The SandPaper

Until November 1912, 48-year-old Elizabeth Kite was a little-known, European-educated social worker from Philadelphia who was working for the state of New Jersey. On the 25th, the Los Angeles Times along with papers across the country ran SELL BABIES IN NEW JERSEY. Report Charges People Also Exchange Wives in Mosquito State.

A report charging people in the Pine section of New Jersey with exchanging wives and selling babies for small sums of money lies on the desk of Gov. Wilson. The report was prepared by Miss Elizabeth Kite, investigator for the State Department of Charities and Corrections.

The Daily Record, a Long Branch, N.J., paper, investigated.

Elizabeth Kite ... has been making a study of conditions in New Jersey relating to degeneracy and feeble mindedness as existing in The Pines including sections of Burlington, Atlantic and Ocean counties.

Miss Kite has spent three years among the people of this District, and her report made to the state commissioner of charities ... maintains that the low type of people of The Pines think nothing of trading their wives and selling their children. Substantiation of her statements can be had by a number of recent cases which have been investigated. Wives are traded and children are sold, according to the society, for small sums of money and for liquor.

Kites report, which was published in October 1913, did give an example.

Only a few years ago a notorious Piney bearing a perverted Huguenot name died in his cabin in the heart of the pines at the age of ninety-eight.

Four years before his death he was found one day returning to his shack after a prolonged absence. Questioned as to where he had been, he said he had gotten tired o the gal he had been livin with too giddy he said shaking his head, too giddy fer me, so I took her down shore an traded her. Did pretty well, too got this old hoss and this here keg orum.

Such conditions are common today in the Pines and many another Piney can be found whose ancestry could be traced back to some off-shoot of a rigid, highly respectable, intelligent family which in other branches, has furnished us some of our best citizens.

Kite, who was a supporter of the new science of eugenics, felt many of the people living in the Pines were the descendants of what she called outcasts from society, deserters from the British Army, criminals and a product of inbreeding, and had become a unique society. She even blamed the French.

Prince Joseph Bonaparte held his miniature court at Bordentown, many were the revels and hunting parties in the Pines which were indulged in by the members of his suite. All these revelers came back, leaving a train of nameless offspring to complicate still further the mixed social problem of the pines, so that today, in tracing the ancestry of any particular group, one runs up continually against the impossibility of proving exact ancestry.

Gov. Woodrow Wilson had just been elected president. As a lame duck, he awaited his inauguration and for the most part remained silent. But the newspapers of the day did not. The Trenton Times of Dec. 26, 1912, declared, Marrying and intermarrying into defective and often imbecile families, the stock has dropped lower in the human scale with each succeeding generation until the State, now finds that it has numbers of small communities scattered through the pines in which practically every inhabitant shows signs of degeneracy. Science, in fact, brands them as a people lost irrevocably to society and civilization. Neither education nor religious influence can aid a people, the scientists say, whose defective adult minds are capable of no greater mental perception than those of children of 9 or 10 years.

Children of this stock, science says and this is the most serious phase of the problem from any viewpoint are doomed by the law of heredity to become a menace to the community and a burden to the State.

The paper focused on the perceived condition of the children, saying, It is the pitiable cases of the children of these Pineys that opened the eyes of the Department of Charities and Corrections to the need for immediate steps to remedy as far as possible the conditions that now exist. Often deserted by their parents, frequently living more like wild animals than human beings, sometimes throughout the summer months wearing little or no covering for their bodies, and suffering in winter from lack of proper clothing, the lot of these children is desperate beyond the power of narration. Efforts made to help them by placing some of these children in good homes in different parts of the state, to be brought up under the intelligent, loving care of foster parents, has shown a pitiable failure of such charitable effort.

Kite in her report wasnt so kind.

The general opinion current regarding the Piney and his class, has been that he is what he is from environment, that surrounded with other conditions and given a chance he would come out all right. That he is a problem, that his presence tends to lower standards of living among the normal people who come in contact with him, is a universally recognized fact, but until recently it has been confidently hoped that through education and the opening up of the Pines, he would eventually become a normal citizen. But the real Piney has no inclination to labor, submitting to every privation in order to avoid it. Lazy, lustful and cunning, he is a degenerate creature who has learned to provide for himself the bare necessities of life without entering into lifes stimulating struggle. Like the degenerate relative of the crab that ages ago gave up a free roving life and, gluing its head to a rock, built a wall of defence around itself, spending the rest of its life kicking food into its mouth and enjoying the functionings of reproduction, the Piney and all the rest of his type have become barnacles upon our civilization.

By March 1913, Wilson was in Washington, but the progressive urban newspapers still had their cause. The Philadelphia Record stated, After spending millions of dollars in corrective measures and worrying a hundred years with the economic problems presented by the criminally degenerate element of the inhabitants of the pine belt, including parts of Burlington, Monmouth and Ocean counties, New Jersey is now seeking a method of halting the spread of this defective race.

It is as cruel for the State to permit these children of degenerate parentage to remain at large as it would be to neglect those suffering from some terrible malady, says Miss Kite. Many of the children are imbeciles, and the conditions in which they live are often horrifying.

To support the claims, the Record presented, One woman has three husbands, all living, bearing children to each, while her present husband has had two previous wives, also living. According to the remarkable story of another woman, she grew tired of her man, and finding no other way to get rid of him, she got the aid of a negro in hanging him to a tree when he was drunk. His death appears on the county records as a suicide.

In another case, a girl of sixteen married an old man of sixty-eight. The bait the old fellow offered was that when he died, which looked like an early prospect, she would get his pension. What his four or five other wives the department has since discovered would have said about the pension arrangement was not considered.

To be sure, the urban newspaper had to point out, Strangely enough, some of the worst examples of this degenerate race are found near the splendid winter resorts springing up in the pines. It is only a step from Browns-Mills-in-the-Pines, where wealth and fashion of Philadelphia and New York winters, into communities of little groups of huts where humanity has touched its lowest level. And the wonderful fertility of this sandy soil, as demonstrated where Italian immigrants have grubbed out the pine stumps and planted truck crops, shows what the Pineys could have done.

The paper quoted Kite as saying, When the State finds a way of eliminating this degeneracy and is courageous enough to put it into effect, we shall have gone a long way toward settling the criminal problem. In this investigation we find we are dealing with crime and degeneracy as a heredity disease. The present criminal element among the Pineys can scarcely be held personally responsible for their short-comings. The department is seeking facts and uncovering these unsavory conditions only that it may aid where immediate aid is needed and, in the hope, that it will open a way to stamp out such conditions in the future.

What did Kite mean by stamp out? What did the progressive science of eugenics have in mind for the Jersey Pine Barrens?

Next Week: The governor visits the Pines.

tpfcjf@comcast.net

View original post here:

Selling Babies, Trading Wives - By THOMAS P. FARNER - The SandPaper

Lilly Presents Positive Results for Taltz (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European…

INDIANAPOLIS, Oct. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with moderate to severe plaque psoriasis, demonstrating that 89 percent of patients treated with Taltz achieved a significant 75 percent improvement from baseline to Week 12 on their Psoriasis Area and Severity Index score (PASI 75) and 81 percent of patients treated with Taltz achieved a static Physician's Global Assessment of clear or almost clear skin (sPGA 0,1). Results of the study are being presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress (EADV) in Madrid, Spain. Based on these positive results, Lilly plans to submit for U.S. regulatory approval for pediatric patients with moderate to severe plaque psoriasis.

"Results from our study indicate that Taltz may have the potential to clear skin and reduce itch in pediatric patients with moderate to severe plaque psoriasis," said study investigator Kim Papp, MD, PhD, Probity Medical Research, Inc., Waterloo, Ontario, Canada. "While it is estimated that up to one third of people with psoriasis first develop symptoms during childhood, there are limited medications available for pediatric patients. This study provides encouraging data supporting the potential for Taltz to become another treatment option for this patient population."

The co-primary endpoints of the study were the proportion of patients achieving a significant 75 percent improvement from baseline on their Psoriasis Area and Severity Index score (PASI 75) and a static Physician's Global Assessment of clear or almost clear skin (sPGA 0,1) at Week 12. Key secondary endpoints included the proportion of patients achieving PASI 90, sPGA (0) and PASI 100 at Week 12, and at least a four-point improvement in Itch Numeric Rating Scale (Itch NRS 4) among patients with baseline Itch NRS 4 at Week 12, as well as PASI 75 and sPGA 0,1 at Week 4. The proportion of patients achieving 0 or 1 on the Children's Dermatology Life Quality Index (CDLQI, patients 6 to 16 years old) or DLQI (patients 17 years old) at Week 12 was also evaluated.

"We recognize that psoriasis can have a significant impact on children and adolescents, causing challenging symptoms and affecting their self-esteem and ability to connect to peers," said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. "We're pleased to see positive results for Taltz in pediatric patients. These results build on more than five years of safety and efficacy data in adults and support the potential for Taltz in this new population, pending regulatory approvals."

A total of 201 patients aged 6 to <18 years of age with moderate to severe plaque psoriasis were randomized to receive Taltz (20 mg for <25 kg, 40 mg for 25-50 kg or 80 mg for >50 kg through Week 12, with 40 mg, 80 mg or 160 mg starting doses, respectively) or placebo. At 12 weeks, the proportion of patients achieving the co-primary endpoints was superior to placebo with statistically significant difference (P<0.001), including:

Taltz also met all major secondary endpoints in the study (P<0.001).

In this trial, the overall safety profile of Taltz was consistent with previously reported results. The Taltz safety profile has been studied across 15 clinical trials in plaque psoriasis and psoriatic arthritis, with 6,989 patients receiving Taltz, with a total exposure of 16,586 patient-years.1,2,3

INDICATIONS AND USAGE FOR TALTZTaltz is approved for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Taltz is also approved for the treatment of adults with active psoriatic arthritis and active ankylosing spondylitis.

IMPORTANT SAFETY INFORMATION FOR TALTZ

CONTRAINDICATIONSTaltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONSInfectionsTaltz may increase the risk of infection. In clinical trials of patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of patients with psoriatic arthritis and ankylosing spondylitis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for TuberculosisEvaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

HypersensitivitySerious hypersensitivity reactions, including angioedema and urticaria (each 0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel DiseaseDuring Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease. Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz 80 mg Q2W group (Crohn's disease 0.1%, ulcerative colitis 0.2%) than in the placebo group (0%) during clinical trials in patients with plaque psoriasis and in the Taltz Q4W group in ankylosing spondylitis trials (Crohn's disease 1.0% [2 patients], ulcerative colitis 0.5% [1 patient]) than in the placebo group (Crohn's disease 0.5% [1 patient], ulcerative colitis 0%). In the ankylosing spondylitis trials, serious events occurred in 1 patient in the Taltz group and 1 patient in the placebo group.

ImmunizationsPrior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

ADVERSE REACTIONSMost common adverse reactions (1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in patients with psoriatic arthritis and ankylosing spondylitis were consistent with the safety profile in patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis.

Please see accompanying Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.

IX HCP ISI 23AUG2019

About TaltzTaltz (ixekizumab) is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.4 IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Taltz inhibits the release of pro-inflammatory cytokines and chemokines.4

About Moderate to Severe Plaque Psoriasis Psoriasis is a chronic, immune disease that affects the skin.5 It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis affects approximately 125 million people worldwide, approximately 20 percent of whom have moderate to severe plaque psoriasis.5,6 The most common form of psoriasis, plaque psoriasis, appears as raised, red patches covered with a silvery white buildup of dead skin cells.5 Patients with plaque psoriasis often have other serious health conditions, such as diabetes and heart disease and experience negative impact on their quality of life.5

About the Phase 3 Pediatric Study This study is a Phase 3, multicenter, randomized, double-blinded, placebo controlled study to evaluate safety, tolerability and efficacy of Taltz in patients from 6 to <18 years of age with moderate to severe plaque psoriasis. The co-primary endpoints of the study were the proportion of patients achieving a 75 percent improvement from baseline on their Psoriasis Area and Severity Index score (PASI 75) and a static Physician's Global Assessment of clear or almost clear skin (sPGA 0,1) at Week 12. Key secondary endpoints included the proportion of patients achieving PASI 90, sPGA 0 and PASI 100 at Week 12, and at least a four-point improvement in Itch numeric rating scale (Itch NRS 4) among patients with baseline Itch NRS 4 at Week 12, as well as PASI 75 and sPGA 0,1 at Week 4. The proportion of patients achieving 0 or 1 on the Children's Dermatology Life Quality Index (CDLQI, patients 6 to 16 years old) or DLQI (patients 17 years old) at Week 12 was also evaluated.

About Lilly in DermatologyBy following the science through unchartered territory, we continue Lilly's legacy of delivering innovative medicines that address unmet needs and have significant impacts on people's lives around the world. Skin-related diseases are more than skin deep. We understand the devastating impact this can have on people's lives. At Lilly, we are relentlessly pursuing a robust dermatology pipeline to provide innovative, patient-centered solutions so patients with skin-related diseases can aspire to live life without limitations.

About Eli Lilly and CompanyLilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom. P-LLY

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Taltz (ixekizumab) as a potential treatment for pediatric patients with moderate to severe plaque psoriasis, and reflects Lilly's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with the results to date, that Taltz will receive additional regulatory approvals, or be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertake no duty to update forward-looking statements to reflect events after the date of this release.

1 Data on file. Lilly USA, LLC. TAL20171211A.2 Data on file. Lilly USA, LLC. DOF-IX-US-0019.3 Mease P, Roussou E, Burmester GR, et al. Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials. Arth Care Res. 2018 (Epub). doi:10.1002/acr.23738.4 Taltz Prescribing Information, 2019.5 Psoriasis media kit. National Psoriasis Foundation website. https://www.psoriasis.org/sites/default/files/for-media/MediaKit.pdf. Accessed September, 2019.6 Skin conditions by the numbers. American Academy of Dermatology website. https://www.aad.org/media/stats/conditions/skin-conditions-by-the-numbers. Accessed September, 2019.

SOURCE Eli Lilly and Company

https://www.lilly.com/

Go here to see the original:

Lilly Presents Positive Results for Taltz (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European...

AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress -…

- Twenty new abstracts underscore AbbVie's commitment to advancing standards of care for people living with serious skin diseases

- Results from the LIMMitless trial evaluating continued safety and efficacy with SKYRIZI (risankizumab) in patients with moderate to severe plaque psoriasis at 2.5 years will be presented

- Safety and efficacy data up to 24 weeks will be presented from risankizumab Phase 2 investigational studies for the treatment of active psoriatic arthritis

- New data from a Phase 2b investigational study evaluating time to treatment response with upadacitinib for patients with atopic dermatitis

NORTH CHICAGO, Ill., Oct. 9, 2019 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, today announced that it will present new results evaluating the safety and efficacy of SKYRIZI (risankizumab) at 2.5 years in adult patients with moderate to severe plaque psoriasis, as well as additional data on HUMIRA (adalimumab) and the investigational JAK inhibitor upadacitinib, at the 28th European Academy of Dermatology and Venereology (EADV) Congress, October 9-13, in Madrid.

"Leveraging more than two decades of clinical experience with HUMIRA, AbbVie recently expanded its dermatology portfolio with the approval of SKYRIZI for patients living with moderate to severe plaque psoriasis," said Marek Honczarenko, MD, PhD, vice president, global immunology development, AbbVie. "The new data presented at EADV will advance the knowledge around new and existing treatments for serious skin diseases, like psoriasis, as well as diseases with high levels of unmet need, such as atopic dermatitis and hidradenitis suppurativa."

In addition to sharing new long-term data from the LIMMitless open-label extension study in moderate to severe plaque psoriasis, AbbVie will share results from its ongoing investigational Phase 2 program evaluating risankizumab for the treatment of psoriatic arthritis. Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

In addition, Phase 2b results evaluating time to treatment response with upadacitinib, an oral JAK inhibitor, under investigation for patients with moderate to severe atopic dermatitis will be shared as an oral presentation. Upadacitinib is not approved for atopic dermatitis by any regulatory authority, and its safety and efficacy have not been established in this indication.

Additional presentations include efficacy and safety results further evaluating HUMIRA in hidradenitis suppurativa.

"Chronic skin diseases can have a significant physical and psychosocial impact on patients," said Jean-Marie Meurant, board president of the International Alliance of Dermatology Patient Organizations. "While progress has been made to improve the lives of patients, many still do not have access to the treatment and care they need and deserve. It's critical that the scientific community build upon current research to better understand these diseases and continue to keep the patient experience at the forefront of their efforts."

AbbVie Data at EADV

Risankizumab Abstracts Psoriasis

Psoriatic arthritis

Upadacitinib AbstractsAtopic dermatitis

HUMIRA AbstractsPsoriasis

Hidradenitis suppurativa

Disease State AbstractsHidradenitis suppurativa

About SKYRIZI (risankizumab) in the EU1

SKYRIZI (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Important EU Safety Information1

SKYRIZI is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients and in clinically important active infections. SKYRIZI may increase the risk of infection. In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, SKYRIZI should be used with caution. Treatment with SKYRIZI should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.

Prior to initiating treatment with SKYRIZI, patients should be evaluated for tuberculosis (TB) infection. Patients receiving SKYRIZI should be monitored for signs and symptoms of active TB. Anti-TB therapy should be considered prior to initiating SKYRIZI in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.

Story continues

The most frequently reported adverse reactions were upper respiratory infections, which occurred in 13 percent of patients. Commonly (greater than or equal to 1/100 to less than 1/10) reported adverse reactions included tinea infections, headache, pruritus, fatigue and injection site reactions.

This is not a complete summary of all safety information. See the full summary of product characteristics (SmPC) at http://www.ema.europa.eu. Globally, prescribing information varies; refer to the individual country product label for complete information.

About Upadacitinib

Discovered and developed by AbbVie, upadacitinib is an investigational, oral, small molecule JAK inhibitor being studied for moderately to severely active rheumatoid arthritis and other immune-mediated inflammatory diseases.2-15 Phase 3 trials of upadacitinib in psoriatic arthritis, Crohn's disease, atopic dermatitis and ulcerative colitis are ongoing and it is also being investigated to treat ankylosing spondylitis and giant cell arteritis.10-15

About HUMIRA in the EU16

HUMIRA is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.

HUMIRA is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy.

Important EU Safety Information16

HUMIRA is contraindicated in patients with active tuberculosis or other severe infections such as sepsis, and opportunistic infections and in patients with moderate to severe heart failure (NYHA class III/IV). It is also contraindicated in patients hypersensitive to the active substance or to any of the excipients; serious allergic reactions including anaphylaxis have been reported. The use of HUMIRA increases the risk of developing serious infections, including hepatitis B reactivation, which may, in rare cases, be life-threatening. Rare cases of lymphoma and leukemia have been reported in patients treated with HUMIRA. On rare occasions, a severe type of cancer called hepatosplenic T-cell lymphoma has been observed and often results in death. A risk for the development of malignancies in patients treated with TNF-antagonists cannot be excluded. Rare cases of pancytopenia, aplastic anaemia, demyelinating disease, lupus, lupus-related conditions and Stevens-Johnson syndrome have been reported in patients treated with HUMIRA. The most frequently reported adverse events across all indications included respiratory infections, injection site reactions, headache and musculoskeletal pain.

This is not a complete summary of all safety information. Globally, prescribing information varies; refer to the individual country product label for complete information.

Full summary of product characteristics is available at: http://www.ema.europa.eu

About AbbVie

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at http://www.abbvie.com. Follow @abbvie on Twitter, Facebook, LinkedIn or Instagram.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2018 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References:

View original content:http://www.prnewswire.com/news-releases/abbvie-announces-new-data-from-its-dermatology-portfolio-and-pipeline-at-the-28th-european-academy-of-dermatology-and-venereology-eadv-congress-300934529.html

See the rest here:

AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress -...

Scots psoriasis sufferer opens up on how skin condition can affect mental health and leave her not wanting to – The Scottish Sun

A SCOTS psoriasis sufferer has told how the condition has impacted her relationship by leaving her not wanting to be "touched, cuddled or kissed".

Jude Duncan, 26, has had the irritating skin condition for six years and says it can affect intimate relationships and dating.

4

The marketing officer, who is a 'Skinfluencer' on Instagram has been with her boyfriend for two years and says she is lucky that he is very supportive.

But she also has moments where her itchy and flaky skin affects her mental health and leaves her not wanting intimacy.

Psoriasis, which affects around 2 per cent of people in the UK, is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales.

Jude, from Gourock, told the Scottish Sun: "Im very lucky to have a supportive partner but I know that if I'm not having a great nights sleep, and tossing and turning, then hes not getting a great nights sleep and that can have an impact on them as well.

"Actually having that communication with a partner is really important but it can be really difficult as well for people to open up.

"I'm in a lucky position where I feel very confident with my psoriasis but also sometimes it has felt like if I'm having a flare up I dont want to be touched, I dont want to cuddled, I dont want to be kissed. So it does have that impact on it.

4

"I wouldn't say that because Im with someone I havent had those difficulties."

She added: "Its very hard to get your partner to understand what you're going through mentally as well as the physical aspect of it.

"And the fact that they cant do anything to help puts a strain on it, so its just different."

Jude also had a period of time before she was in a relationship where she was trying to date - but potential suitors were put off by her condition.

She has hit out at the 'Insta perfect' world which means people can be very shallow and focus on a person's perceived flaws.

She said: "On every date I would be asked 'what's wrong with your face' and stuff like that, so it was definitely a topic of conversation.

4

4

"It was the elephant in the room, like when is this going to be brought up.' And thats not how it should be.

"It shouldnt matter if I have a bit of psoriasis on my face or not whether you want a second date, but it really did impact that a lot.

"We live in this Insta perfect world where people with flaws or differences arent seen to be good enough and people dont want to be seen with someone like that.

"But to be honest with you if you have a problem with how I look, I dont really want to date anyone that treats people like that anyway."

Negative affect on Mental Health

Speaking on Mental Health day, Jude explained how various factors surrounding the condition can affect a person's mental wellness.

That includes the discomfort itself, but also the negative impact of how other people treat you.

Stats show that 67 per cent of sufferers believe that the condition can have an affect on your mental health.

Jude said: "If you are uncomfortable and thats causing you to not sleep then thats going to have an affect on your mental health, but also just that uncomfortableness all the time, being in a constant state of irritation, not being able to relax - that is going to have a toll on your mental health.

"A lot of people are like oh lets focus on treating the skin but they dont look at surrounding factors such as mental health.

"Because its such a visual condition it can make you incredibly insecure and really lonely and isolated because it's not really talked about. So that can also have an impact on your mental health because you feel like youre bottling it up and not talking about it.

"If youre not getting any sleep that means the next day you're not going to be functioning to your full potential, and you're stressing yourself out because you're not maybe getting as much done as you want and that's going to result in you stressing out more, which is going to affect your sleep, which is going to affect your mental health and its just a really vicious cycle.

Mental health stats:

Sleep stat:

Relationships stat:

Public perception stat:

Call to action

Latest

STREET DRAMA Watch as police lock down Maryhill Street for 'siege' at Glasgow flat

Exclusive

BRAWL BRUTE Chef battered with baseball bat by Motherwell ace furious at Scotland call-up

NASTY WEATHER Judith Ralston drops F-bomb as she fluffs weather report on BBC Scotland news

Exclusive

JAIL REVENGE Gang rival of Steven 'Bonzo' Daniel held down and repeatedly stabbed in head

Graphic warning

DOG FIGHT SICKO Ayr brute bought cats on Gumtree to use as bait for dogs to rip apart

LOSE CRUISE Angry cruise passengers stage mutiny after their tour swaps Norway for GREENOCK

"I think for me as well, when people stare or make comments, sometimes they mean well but that can really also play on your mental health."

She added: "I definitely had comments in the past. I've had people say really horrible things to my face.

"But I'm OK that in that I'm in a position where I'm confident enough. There's so many people out there that arent and a situation like that would knock their confidence.

"I was in a position that I was able to move on and deal with it but thats not always the case."

If you are affected by any of the issues raised in this article, please call the Samaritans on (free) 116123.

We pay for your stories and videos! Do you have a story or video for The Scottish Sun? Email us at scoop@thesun.co.uk or call 0141 420 5300

Read more from the original source:

Scots psoriasis sufferer opens up on how skin condition can affect mental health and leave her not wanting to - The Scottish Sun

Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology…

Research from Taltz, Olumiant and mirikizumab highlight the impact Lilly's medicines may have for patients around the world

INDIANAPOLIS, Oct. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will present new data for Taltz (ixekizumab), Olumiant (baricitinib) and mirikizumab at the 28th annual European Academy of Dermatology and Venereology (EADV) Congress taking place Oct. 9-13 in Madrid, Spain. The research being highlighted at this year's meeting reinforces Lilly's commitment to developing treatments for individuals living with dermatological conditions such as psoriasis, psoriatic arthritis, atopic dermatitis and alopecia areata.

"Lilly is proud to showcase data from our dermatology portfolio at EADV this year. Our scientific expertise in dermatology has helped increase the number of available treatment options for patients around the world living with skin-related diseases," said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. "We aspire to raise expectations as to how these diseases are treated so people can live their lives without compromise."

Lilly will present findings from a Phase 3 trial of Taltz for pediatric patients with moderate to severe psoriasis as a late-breaking oral presentation at this year's meeting. The company also will be sharing results from a patient survey evaluating treatment expectations and burden of disease for patients living with psoriasis.

For baricitinib, Lilly will present a late-breaking presentation of the BREEZE-AD7 clinical trial. BREEZE-AD7 is an investigational study measuring the efficacy and safety of baricitinib in combination with topical corticosteroids for the treatment of moderate to severe atopic dermatitis (AD) in adults. Lilly and Incyte Corporation (NASDAQ: INCY) are partners in the clinical development of baricitinib. Further, Lilly will present data findings from a real-world study assessing how elements of an individual's quality of life (both functional and emotional) may be impacted by AD.

Posters to be shared around Lilly's investigational compound, mirikizumab, include research from a study measuring patient outcomes and health-related elements of quality of life for individuals with moderate to severe psoriasis.

Studies, along with the times and locations for the data sessions, are highlighted below.

Taltz Data

Oral Presentations

Thursday, October 10

Saturday, October 12

Poster Presentations

Baricitinib Data

Oral Presentations

Saturday, October 12

Poster Presentations

Mirikizumab Data

Poster Presentations

INDICATIONS AND USAGE FOR TALTZTaltz is approved for the treatment of adults with adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Taltz is also approved for the treatment of adults with active psoriatic arthritis and active ankylosing spondylitis.

IMPORTANT SAFETY INFORMATION FOR TALTZ

CONTRAINDICATIONSTaltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS InfectionsTaltz may increase the risk of infection. In clinical trials of patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of patients with psoriatic arthritis and ankylosing spondylitis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for TuberculosisEvaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

HypersensitivitySerious hypersensitivity reactions, including angioedema and urticaria (each 0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel DiseaseDuring Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease. Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz 80 mg Q2W group (Crohn's disease 0.1%, ulcerative colitis 0.2%) than in the placebo group (0%) during clinical trials in patients with plaque psoriasis and in the Taltz Q4W group in ankylosing spondylitis trials (Crohn's disease 1.0% [2 patients], ulcerative colitis 0.5% [1 patient]) than in the placebo group (Crohn's disease 0.5% [1 patient], ulcerative colitis 0%). In the ankylosing spondylitis trials, serious events occurred in 1 patient in the Taltz group and 1 patient in the placebo group.

ImmunizationsPrior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

ADVERSE REACTIONSMost common adverse reactions (1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea and tinea infections. Overall, the safety profiles observed in patients with psoriatic arthritis and ankylosing spondylitis were consistent with the safety profile in patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis.

Please see accompanying Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.

IX HCP ISI 23AUG2019

Indication and Usage for OLUMIANT (baricitinib) tablets (in the United States) for RA patientsOLUMIANT (baricitinib) 2 mg is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. Limitation of Use: Use of OLUMIANT in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

IMPORTANT SAFETY INFORMATION FOR OLUMIANT (baricitinib) TABLETS

WARNING: SERIOUS INFECTIONS, MALIGNANCY, AND THROMBOSIS

SERIOUS INFECTIONS: Patients treated with Olumiant are at risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. If a serious infection develops, interrupt Olumiant until the infection is controlled. Reported infections include:

Carefully consider the risks and benefits of Olumiant prior to initiating therapy in patients with chronic or recurrent infection.

Closely monitor patients for the development of signs and symptoms of infection during and after treatment with Olumiant including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

MALIGNANCIES: Lymphoma and other malignancies have been observed in patients treated with Olumiant.

THROMBOSIS: Thrombosis, including deep venous thrombosis (DVT) and pulmonary embolism (PE), has been observed at an increased incidence in patients treated with Olumiant compared to placebo. In addition, there were cases of arterial thrombosis. Many of these adverse events were serious and some resulted in death. Patients with symptoms of thrombosis should be promptly evaluated.

WARNINGS AND PRECAUTIONS

SERIOUS INFECTIONS: The most common serious infections reported with Olumiant included pneumonia, herpes zoster and urinary tract infection. Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus and BK virus were reported with Olumiant. Some patients have presented with disseminated rather than local disease and were often taking concomitant immunosuppressants such as methotrexate or corticosteroids. Avoid Olumiant in patients with an active, serious infection, including localized infections. Consider the risks and benefits of treatment prior to initiating Olumiant in patients:

Closely monitor patients for infections during and after Olumiant treatment. Interrupt Olumiant if a patient develops a serious infection, an opportunistic infection, or sepsis. Do not resume Olumiant until the infection is controlled.

Tuberculosis Before initiating Olumiant evaluate and test patients for latent or active infection and treat patients with latent TB with standard antimycobacterial therapy. Olumiant should not be given to patients with active TB. Consider anti-TB therapy prior to initiating Olumiant in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection. Monitor patients for TB during Olumiant treatment.

Viral Reactivation Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), were reported in clinical studies with Olumiant. If a patient develops herpes zoster, interrupt Olumiant treatment until the episode resolves.

The impact of Olumiant on chronic viral hepatitis reactivation is unknown. Screen for viral hepatitis in accordance with clinical guidelines before initiating Olumiant.

MALIGNANCY AND LYMPHOPROLIFERATIVE DISORDERS: Malignancies were observed in Olumiant clinical studies. Consider the risks and benefits of Olumiant prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer (NMSC) or when considering continuing Olumiant in patients who develop a malignancy. NMSCs were reported in patients treated with Olumiant. Periodic skin examination is recommended for patients who are at increased risk for skin cancer.

THROMBOSIS: Thrombosis, including DVT and PE, has been observed at an increased incidence in Olumiant-treated patients compared to placebo. In addition, arterial thrombosis events in the extremities have been reported in clinical studies with Olumiant. Many of these adverse events were serious and some resulted in death. There was no clear relationship between platelet count elevations and thrombotic events. Use Olumiant with caution in patients who may be at increased risk of thrombosis. If clinical features of DVT/PE or arterial thrombosis occur, evaluate patients promptly and treat appropriately.

GASTROINTESTINAL PERFORATIONS: Gastrointestinal perforations have been reported in Olumiant clinical studies, although the role of JAK inhibition in these events is not known. Use Olumiant with caution in patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis). Promptly evaluate patients who present with new onset abdominal symptoms for early identification of gastrointestinal perforation.

LABORATORY ABNORMALITIES: Neutropenia Olumiant treatment was associated with an increased incidence of neutropenia (absolute neutrophil count [ANC] <1000 cells/mm3) compared to placebo. Avoid initiation or interrupt Olumiant treatment in patients with an ANC <1000 cells/mm3. Evaluate at baseline and thereafter according to routine patient management.

Lymphopenia Absolute lymphocyte count (ALC) <500 cells/mm3 were reported in Olumiant clinical trials. Lymphocyte counts less than the lower limit of normal were associated with infection in patients treated with Olumiant, but not placebo. Avoid initiation or interrupt Olumiant treatment in patients with an ALC <500 cells/mm3. Evaluate at baseline and thereafter according to routine patient management.

Anemia Decreases in hemoglobin levels to <8 g/dL were reported in Olumiant clinical trials. Avoid initiation or interrupt Olumiant treatment in patients with hemoglobin <8 g/dL. Evaluate at baseline and thereafter according to routine patient management.

Liver Enzyme Elevations Olumiant treatment was associated with increased incidence of liver enzyme elevation compared to placebo. Increases to 5x and 10x upper limit of normal were observed for both ALT and AST in patients in Olumiant clinical trials.

Evaluate at baseline and thereafter according to routine patient management. Promptly investigate the cause of liver enzyme elevation to identify potential cases of drug-induced liver injury. If increases in ALT or AST are observed and drug-induced liver injury is suspected, interrupt Olumiant until this diagnosis is excluded.

Lipid Elevations Treatment with Olumiant was associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol. Assess lipid parameters approximately 12 weeks following Olumiant initiation. Manage patients according to clinical guidelines for the management of hyperlipidemia.

VACCINATIONS: Avoid use of live vaccines with Olumiant. Update immunizations in agreement with current immunization guidelines prior to initiating Olumiant therapy.

ADVERSE REACTIONSAdverse reactions (1%) include: upper respiratory tract infections (16.3%, 14.7%, 11.7%), nausea (2.7%, 2.8%, 1.6%), herpes simplex (0.8%, 1.8%, 0.7%) and herpes zoster (1.0%, 1.4%, 0.4%) for Olumiant 2 mg, baricitinib 4 mg, and placebo, respectively.

USE IN SPECIFIC POPULATIONSPREGNANCY AND LACTATION: No information is available to support the use of Olumiant in pregnancy or lactation. Advise women not to breastfeed during treatment with Olumiant.

HEPATIC AND RENAL IMPAIRMENT: Olumiant is not recommended in patients with severe hepatic impairment or in patients with moderate or severe renal impairment.

Please click to access full Prescribing Information, including Boxed Warning about Serious infections, Malignancies, and Thrombosis, and Medication Guide.

BA HCP ISI 01JUN2018

About Taltz Taltz (ixekizumab) is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.1 IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Taltz inhibits the release of pro-inflammatory cytokines and chemokines.1

About OLUMIANT OLUMIANT is a once-daily, oral JAK inhibitor approved in the U.S. for the treatment of adults with moderately- to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF inhibitor therapies, and approved outside of the U.S. for patients with moderately- to severely active rheumatoid arthritis who have had an inadequate response to one or more DMARDs.2 There are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2. JAK-dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoimmune diseases.3 OLUMIANT has greater inhibitory potency at JAK1, JAK2 and TYK2 relative to JAK3; however, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.2 OLUMIANT is approved in more than 60 countries.

About Mirikizumab Mirikizumab is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of interleukin 23. Mirikizumab is being studied for the treatment of immune diseases, including psoriasis, ulcerative colitis and Crohn's disease.

About Moderate to Severe Plaque Psoriasis Psoriasis is a chronic, immune disease that affects the skin.4 It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis affects approximately 125 million people worldwide, approximately 20 percent of whom have moderate to severe plaque psoriasis.4,5 The most common form of psoriasis, plaque psoriasis, appears as raised, red patches covered with a silvery white buildup of dead skin cells.4 Patients with plaque psoriasis often have other serious health conditions, such as diabetes and heart disease and experience negative impact on their quality of life.4

About Atopic DermatitisAtopic dermatitis (AD), a serious form of atopic eczema, is a chronic, relapsing skin disease characterized by intense itching, dry skin and inflammation that can be present on any part of the body.6 AD is a heterogeneous disease both clinically and biologically, but may be characterized by chronic baseline symptoms of itch, redness and skin damage that are often punctuated with episodic, sometimes unpredictable, flares or exacerbations.7,8 AD affects approximately 1-3 percent of adults worldwide.9

Moderate to severe AD is characterized by intense itching, resulting in visibly damaged skin.10 Like other chronic inflammatory diseases, AD is immune-mediated and involves a complex interplay of immune cells and inflammatory cytokines.11

About BREEZE-AD7The BREEZE-AD7 clinical trial is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study that evaluated the efficacy and safety of baricitinib in combination with topical corticosteroids in adult patients with moderate to severe atopic dermatitis. Two doses were evaluated separately such that the primary objective of the study could be met if one or both doses achieved the primary endpoint. The primary endpoint evaluated significant improvement in disease activity as determined by the proportion of patients on baricitinib achieving clear (0) or almost clear skin (1) with a greater than or equal to 2-point improvement as measured by the validated 5-point Investigator's Global Assessment for AD (vIGA) scale at 16 weeks of treatment. BREEZE-AD7 is the third of five Phase 3 studies that make up the BREEZE-AD program. Lilly previously announced results for BREEZE-AD1 and BREEZE-AD2 earlier this year.

About Lilly in DermatologyBy following the science through unchartered territory, we continue Lilly's legacy of delivering innovative medicines that address unmet needs and have significant impacts on people's lives around the world. Skin-related diseases are more than skin deep. We understand the devastating impact this can have on people's lives. At Lilly, we are relentlessly pursuing a robust dermatology pipeline to provide innovative, patient-centered solutions so patients with skin-related diseases can aspire to live life without limitations.

About Eli Lilly and CompanyLilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom. P-LLY

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Taltz (ixekizumab), OLUMIANT (baricitinib), and mirikizumab, and reflects Lilly's and Incyte's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that mirikizumab will receive regulatory approval, that Taltz or OLUMIANT will receive additional regulatory approvals, or that any will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's and Incyte's most recent respective Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly and Incyte undertake no duty to update forward-looking statements to reflect events after the date of this release.

_______________________________1 Taltz Prescribing Information, 2019.2 Olumiant Prescribing Information, 2018.3 Walker JG and Smith MD. J Rheumatol. 2005;32;1650-1653.4 Psoriasis media kit. National Psoriasis Foundation website. https://www.psoriasis.org/sites/default/files/for-media/MediaKit.pdf. Accessed September, 2019.5 Skin conditions by the numbers. American Academy of Dermatology website. https://www.aad.org/media/stats/conditions/skin-conditions-by-the-numbers. Accessed September, 2019.6 Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. The Journal of Allergy and Clinical Immunology. 2006;118: 226-32.7 Thijs JL, Strickland I, Bruijnzeel-Koomen C, et. al. Moving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis. The Journal of Allergy and Clinical Immunology. 2017.8 Langan SM, Thomas KS, Williams HC. What is meant by "flare" in atopic dermatitis? A systematic review and proposal. Arch Dermatol. 2006;142:1190-1196.9 Nutten S. Atopic dermatitis: global epidemiology and risk factors. Annals of Nutrition and Metabolism. 2015;66(suppl 1): 8-16.10 Yosipovitch G, Papoiu AD. What causes itch in atopic dermatitis? Current Allergy and Asthma Reports. 2008;8:306-311.11 Weidinger, S, Novak, N. Atopic dermatitis. The Lancet Volume 387. 2016;10023:1109-1122.

View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-to-unveil-new-data-for-the-treatments-of-complex-dermatological-conditions-at-the-28th-annual-european-academy-of-dermatology-and-venereology-eadv-congress-300933466.html

SOURCE Eli Lilly and Company

Company Codes: NASDAQ-NMS:INCY, NYSE:LLY

View post:

Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology...

Public awareness on psoriasis increasing: health expert – pna.gov.ph

PSORIASIS AWARENESS CAMPAIGN. Dr. Victoria P. Guillano, MD, FPDS, president of the Psoriasis Foundation of the Philippines, Inc. (PFPI) speaks with stakeholders and patients during the World Psoriasis Day celebration in Davao City on Wednesday (Oct. 9, 2019). Guillano says the stigma associated with psoriasis remains but notes that public awareness has continued to increase in the past years. (PNA photo by Digna Banzon)

DAVAO CITY -- The stigma associated with psoriasis disease remains but public awareness continues to increase, a health expert said.

in an interview during the World Psoriasis Day celebration on Wednesday here, Dr. Victoria P. Guillano, MD, FPDS, president of the Psoriasis Foundation of the Philippines, Inc. (PFPI), attributed the increase to more patients seeking treatment .

Guillano said that according to psoriasis patients, the public has slowly learned to understand them.

She said psoriasis is a chronic, immune-mediated inflammatory disease that causes physical, emotional and social burdens.

The presence of associated itch and lesions on visible and sensitive body areas in psoriasis patients are closely related to decreased psychosocial well-being and impact on the quality of life,' she said.

Davao City Mayor Sara Z. Duterte, whose message was read during the celebration, encouraged stakeholders to raise awareness and information on the proper treatment of the disease.

Sara commended the organizing committee of the Southern Philippines Medical Center (SPMC) Department of Dermatology for spearheading the awareness campaign and creating a platform where people with psoriasis can share their experiences and have their voices heard.

I hope this celebration be instrumental in giving the people with psoriasis the access of affordable and appropriate treatment, the mayor said.

Meanwhile, Guillano said psoriasis remains incurable but the skin can be cleared--its treatment ranging from PHP17,000 to PHP250,000 depending on the severity of the case.

"Our campaign includes lecture and wellness programs for the patients and the public as well," she said. (PNA)

See original here:

Public awareness on psoriasis increasing: health expert - pna.gov.ph

IL-41 Levels Elevated in Synovium of Patients With Psoriatic Arthritis – Rheumatology Advisor

Interleukin (IL)-41, also known as Meteorin-like, is expressed in the synovial tissue of patients with psoriatic arthritis (PsA), rheumatoid arthritis (RA), and osteoarthritis (OA), and is present and inducible in the enthesis, according to study results published in Clinical Immunology.

The study included data from patients who were treatment-naive. Researchers extracted synovial fluid and measured IL-41 levels using enzyme-linked immunosorbent assay; results from the synovial fluid had <10% reproducibility error. Cell cultures and receptor analysis by flow cytometry were performed to achieve appropriate samples. Researchers also obtained patient demographics.

Study results indicated that IL-41 was detectable in synovial fluid samples in patients with PsA, RA and OA, although it was significantly higher in PsA and RA compared with OA (median, 7722 pg/mL; P =.0011 and 8325 pg/mL; P =.0003 vs 5044 pg/mL, respectively). Researchers also obtained levels of IL-41 in synovial fluid from patients with gout; it was higher compared with IL-41 in patients with OA, but statistical significance was not achieved.

Researchers investigated the production of IL-41 in healthy enthesis samples and noted that although minimal IL-41 was produced from enthesis mononuclear cells, entheseal stromal cells produced a significant amount of IL-41 in comparison. Synovial fibroblasts also showed similar levels of IL-41 compared with entheseal stromal cells.

In addition, the researchers assessed whether IL-41 could be induced by disease relevant mediators, including tumor necrosis factor (TNF), IL-17A, and IL-17F. Results showed that when used alone, TNF, IL-17A, and IL-17F did not induce an increase in IL-41, but TNF with IL-17A or IL-17F led to a significant increase in IL-41 production. Study investigators observed similar results with synovial fibroblasts.

Overall, IL-41 was significantly elevated in the synovium and was induced from enthesis stromal cells in patients with PsA.

The precise role of IL-41 in PsA immunopathogenesis requires further study, the researchers concluded.

Reference

Bridgewood C, Russell T, Weedon H, et al. The novel cytokine Metrnl/IL-41 is elevated in psoriatic arthritis synovium and inducible from both entheseal and synovial fibroblasts. J Clin Immunol. 2019;208:108253.

Go here to see the original:

IL-41 Levels Elevated in Synovium of Patients With Psoriatic Arthritis - Rheumatology Advisor

Novartis data show Cosentyx treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and wit…

Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites.

ABOUT THIRD PARTY LINKS ON OUR SITE

PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com.

PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.

Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely.

If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.

Read the original post:

Novartis data show Cosentyx treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and wit...

New Guelph exhibit reveals history of eugenics education in Ontario – CBC.ca

Eugenics was taught at the founding colleges of the University of Guelph for more than 30 years at the start of the 20th century, according to documents discovered by a researcher at the school.

Eugenics,often associated with Adolf Hitler and Nazi Germany, is the idea that it's possible to improve the human race through selective breeding, based on traits such as race.

The unearthed documents and other archives, which show support for eugenics in Ontario around the time of the Second World War, are on display as part of a new exhibit at the Guelph Civic Museum called "Into the Light: Eugenics and Education in Southern Ontario."

The exhibit is a collaboration of activists, Indigenous artists and researchers. It's meant to reveal a troubled legacy, but also to share stories of survival.

It opens with an Anishinaabe prayer spoken by one of the co-curators, Mohawk elder Mona Stonefish; a gentle point of entry ahead of what's inside.

It wasn't an easy path to find old course material on eugenics.

Evadne Kelly, a postdoctoral researcher at the Revision Centre for Art and Social Justice who found the documents, remembers searching in a number of University of Guelph archives that came up blank.

"It took quite a bit more digging and also speaking with archivists who were willing to create unrestricted access to these archives," Kelly said.

Kelly said she doesn't believe anybody at the university was aware eugenics had been taught.

"It was really shocking,"Kelly said.

"I think that this history has been obscured ... I don't think people really want to acknowledge that such hurtful and hateful ideas were being taught for decades in Canada."

The search began with a hunch on the part of Kelly's academic supervisor that eugenics may have been taught at one of the founding colleges at the university.

Turns out it was taught at two: Macdonald Institute and the Ontario Agricultural College.

The first sign of eugenics weaving its way into course material was a 1914 biology course. Kelly also found it was taught in psychology courses and a course called mothercraft.

"[Mothercraft] was in my mind one of the more dangerous courses,"Kelly said.

"Students were being taught how much affection is appropriate. What kinds of behaviours are OK and how to punish for behaviours that are not wanted."

Kelly noticed the course material shifted around the Second World War. The language ramped up and became much more nationalistic with anti-immigration sentiments.

One exam question got students to think about policies to sterilize the unfit.

The last time Kelly found evidence of eugenics in course material was 1948, but she suspects the subject matter extends beyond that point.

There is research on eugenics being taught at universities in western Canada, but the archive appears to be the most substantive amount of research on eugenics education in Ontario, according to Kelly.

The University of Guelph course material was just the starting point.

Kelly also found transcripts of radio addresses from Ontario legislators and academics at the University of Toronto and McMaster University in Hamilton. They were pushing for eugenics policies to be applied in the province.

In the corner of the exhibit, there's an old radio and a couple of chairs. Through headphones, people can listen to readings of the old radio messages.

One of the addresses from 1938 is written by former Lieutenant Governor of Ontario Herbert Bruce, praising the sterilization policies of Nazi Germany.

"It is an uncomfortable and difficult history to share," said Dawn Owen, the curator of the Guelph Civic Museum.

"Eugenics was not only theorized about and practiced within the university, but there were multiple decades where the practice of eugenics not only happened locally within this community, but then also because the students who were learning eugenics were then going into teaching professions ...we can actually trace lines into other institutes across the province and, frankly, across the country."

By putting these radio addresses, course material and other artifacts out there for the public, the collaborators hope the exhibit is a move toward reconciliation.

"The message isn't one of hopelessness. The message is one of truth,"Owen said.

"We hope that with truth, with knowledge, that will lead us down the path toward reconciliation."

See the original post:

New Guelph exhibit reveals history of eugenics education in Ontario - CBC.ca

Playing God, Ungodly? – Times of India

How would it be if it were possible to order the birth of a baby girl who would grow to be as beautiful as Venus and as intelligent as Marie Curie? Or the birth of a baby boy who would grow to be as handsome as Adonis and as intelligent as Einstein? How would it be if it were possible to choose the colour of the eyes, hair and skin tone? Does the idea sound outr, utopian? Recent scientific advances indicate that the idea of designer babies is neither all that outr nor all that utopian. It is a possibility in the not too distant future. It is the ethics of the issue that should worry mankind. Is genetic engineering ethical or even desirable?

Man created angels, gods and goddesses in his own image. It is for this reason they are referred to as anthropomorphic gods. In his creation man-made gods and goddesses the most beautiful creatures; again beauty being a product of his own imagination. The creation of anthropomorphic gods is but an expression of mans endless quest to replicate nature or improving upon it. It was an enticing subject that drew artistes and scientists alike. In general, the artistes were wary of the dangers of replicating or improving upon nature. Here are a few examples. Mary Shellys 1918 Gothic novel Frankenstein or The Modern Prometheus described the horrors that would result in tinkering with nature. So did Aldous Huxleys dystopian Brave New World (1932) and Ken Folletts science-fiction The Third Twin (1996), but to a less horrific degree.

But the scientists would not be deterred. For as long as the history of science could be traced, maverick for want of a better word scientists in many nations conducted experiments with the objective of transmuting base metals into gold, to find a universal solvent and to find a potion that would extend longevity. The scientists were collectively known as alchemists. Although for long they were dismissed as charlatans and although they did not achieve the objectives they set out to do, their work had advanced science as far as the purification of metals.

In recent times genetic engineering has been focusing on four areas of human development. They are muscle enhancement to improve athletic performance; memory enhancement to improve intellectual performance; growth hormone treatment to improve physical stature and selection of sex and genetic traits of children. The selection of sex is already a reality. It must be noted that gender screening tests are illegal in India. There are several companies in the USA which already offer sex selection with certain pre-conditions that would preclude its possible misuse. The process/product is offered to only those couples who have one child and who desire to have a child of the opposite sex to balance their families.

The theory of eugenics is as old as Aristotle. It appears the fourth century BCE philosopher had suggested that men should tie their left testicles prior to intercourse if they wanted a male child! In The case against perfection: ethics in the age of genetic engineering (2007), Michael J. Sandel discussed both the pros and cons of genetic engineering.

As societies evolve, old mores give way to new norms. Sandel cites a character from the 1981 British historical film, Chariots of Fire. It was the story of two athletes, Eric Liddell, a devout Scottish Christian and Harold Abrahams, an English Jew who competed in the 1924 Paris Olympics. Prior to 1924, employing professional coaches for training to compete in amateur sport was scoffed at. It was considered ungentlemanly. Abrahams defied the custom as he felt that it was just a cover for anti-Semitism. The point being made is that today employing coaches is an accepted norm. In fact, it is unimaginable for any athlete to go into high-level competitions without a personal trainer.

Much of the opposition to genetic engineering stems from the negative connotations associated with eugenics. The objective of eugenics was to increase the proportion of healthy and intelligent individuals in the general population. Conversely the poor and unhealthy were prevented from conceiving by forced sterilisation. It is generally assumed that forced sterilisations as a measure of eugenics were practised only in Nazi Germany. According to a report published in the website PsychCentral.com, by the 1930s thirty states in the USA had sterilisation laws. Between 1927 when Carrie Buck, the first victim of the Virginia sterilisation law was sterilised and the 1970s, 65,000 Americans with mental illness or developmental disabilities were sterilised. When the Buck case reached the Supreme Court, Justice Oliver Wendell Holmes ruled: It is better for all the world, if instead of waiting to execute degenerate offspring for crime or to let them starve for their imbecility, society can prevent those who are manifestly unfit from continuing their kindThree generations of imbeciles are enough.

To forestall genetic engineering for ethical considerations amounts to throwing the baby out with the bathwater. Scientists believe that the key to finding remedies for diseases like thalassemia and cancer is in genetic engineering.

When the banking industry introduced information technology tools in the 1980s doomsday predictors hollered that it would lead to thousands going out of employment. We live in a world of over the counter (OTC) remedies and food supplements for growth and beauty enhancement. Not an hour passes when we dont see bamboozling advertisements about them on television. Bariatric surgery and cosmetic surgery for beauty enhancement are fairly common with only the cost being the limiting factor. Would it be the only limiting factor for made to order babies too? Or are ethics involved?

Should we, in the end, accept and live with advances in genetic engineering or heed the warning of Mary Shelly and Aldous Huxley about Promethean hubris? The last word in the debate is yet to be pronounced!

DISCLAIMER : Views expressed above are the author's own.

See more here:

Playing God, Ungodly? - Times of India

Alderman Library in midst of removing 1.7 million books, other items – The Daily Progress

By now, the steps are familiar to everyone working in the stacks of Alderman Library: pick a book off the shelf, scan it, fit it into a cardboard tray, scan a barcode on the tray, load trays into orange crates and stack the crates into a truck.

It takes a long time to pack and move 1.7 million books and other library materials across the University of Virginia, but contractor Jacob Bastian estimates his team is halfway done with their part of the job. The project is the first leg of a $160 million renovation of the library, which opened in 1938.

Its not very glamorous, said Bastian, with Backstage Library Services, as he recently wound his way back and forth through various floors of the stacks. But it has to be done.

In 2017, Bastian and fellow project manager Jared Scherer led a team that cataloged Aldermans inventory. The team counted, cleaned and verified each item books, pages, scrolls, maps and items in the building, and fixed thousands of catalog errors.

Theres a lot of little details to a library that you never realize, said Scherer, a graduate of UVa.

The renovation will require demolishing the Old and New Stacks and moving most of the librarys collection off-site to Ivy Stacks; a significant portion will return to Alderman when the renovation is completed.

The cramped 10-floor layout of the Alderman stacks, which were never meant to be open for public browsing and which are not ADA- or fire-code-compliant, will become five stories with compact shelving, more seating and study and class rooms.

The project also will restore the historic MacGregor Reading Room and add an entrance to the north side of the building.

Some faculty and staff opposed the renovation. The new compact shelving system, on which a series of bookshelves are clustered together on a track and a user moves them and can access one set of shelves at a time, will discourage serendipitous browsing, according to petition created in June 2018.

As workers pack books into crates and move them to Ivy Stacks, they are also careful to keep everything in order, because, unlike other moves Backstage has done, most of the items will return to Central Grounds (plus, during the move, all books will remain available for checkout at either Ivy Stacks or Clemons Library).

We dont just haul the books out, said Esther Onega, senior project director of the Alderman renovation. The online catalog must be updated with the new location and the books must remain in call number order so we can bring them back in call number order. It would take a long time to get them back in order if we dont keep them that way.

The buildings quirks also make boxing up books a delicate affair. Workers must navigate the stacks cramped ceilings and wedge crates into a tiny freight elevator.

Aldermans collections are kept according to the Library of Congress classification system, but some sections are scattered across different floors. That means that Scherer and Bastians team, which is currently working its way through the H books (social sciences), are ferrying books from multiple floors down a tiny freight elevator to a loading area.

The team already has identified the books that are most frequently requested, and have ferried items on the hit list to the recently renovated Clemons Library. The first floor of Clemons reopened in May with different study spaces and compact shelves.

Now, most remaining items are on their way to Ivy Stacks, guided by moving subcontractor Overton & Associates.

Once the books are out of Alderman, the metal shelves will be recycled and workers will begin preparing the building for partial demolition. During the spring semester, Historic Alderman will remain open. Construction manager Skanska will begin demolition preparations such as abatement in the stacks and site utility work during the spring semester.

Onega has been planning the move for the past two years.

I used to work in a law firm, and this feels just like finishing up a big case and saying, now what do I do with the rest of my life? she laughed, looking around at now-empty metal shelves.

The university has not yet responded to calls for the renovated library to bear a different name.

Edwin Alderman was the first president of UVa, serving from 1905 to 1931, and helped to organize the modern university. However, he also supported eugenics and the local Ku Klux Klan; in 1921, he thanked the Virginia state Klan for a $1,000 gift to the university (In 2017, former President Teresa A. Sullivan announced a donation equaling the current value of that gift from the university to victims of the Aug. 12, 2017, car attack).

Alderman also delivered the acceptance speech for the Robert E. Lee statue at Market Street Park donated by Paul Goodloe McIntire in 1924 on behalf of the city of Charlottesville.

Several university buildings originally named after eugenicists have been rededicated recently; UVa spokesman Wes Hester did not say whether Alderman has been referred to the universitys committee that considers renamings.

The naming of facilities on the Grounds is an important and ongoing dialogue, and Alderman Library is a part of that conversation, though no decisions have been made at this time, Hester said in an email last week.

Alderman will close in May and the partial demolition will start during the summer of 2020. The project is expected to be completed in phases in the fall of 2022.

Read more here:

Alderman Library in midst of removing 1.7 million books, other items - The Daily Progress


12345...102030...